Active Pharmaceutical Ingredient

Piramal Pharma Solutions opens doors on API production plant

13-Jul-2022 By Jenni Spinner

The contract development and manufacturing organization's active pharmaceutical ingredient manufacturing operation is located at its site in Aurora, Canada.

Inke to triple capacity for inhalation API manufacturing

20-Apr-2022 By Jenni Spinner

The maker of active pharmaceutical ingredients for inhaled treatments is investing €9m ($9.8m USD) to expand its manufacturing plant in Barcelona, Spain.

Sterling expects further HPAPI demand, looks for buy-out opportunities

15-Jan-2020 By Vassia Barba

Sterling continues expansion and lines up further acquisitions, as the HPAPI market continues to see increasing demand, a company executive says.

Almac granted $1m to develop low-cost API manufacturing method

09-Dec-2019 By Vassia Barba

Under funding from Bill and Melinda Gates Foundation, Almac initiates work to develop biosynthetic routes for APIs to be used in world aid programs.

Heraeus adds ‘much-needed’ capacity for chemo components manufacture

25-Nov-2019 By Vassia Barba

Heraeus adds production line to expand its capacity for the manufacture of platinum-based HPAPIs.

Provepharm builds plant to cover its own APIs supply needs

30-Sep-2019 By Vassia Barba

Provepharm expands its facilities in order to manufacture its own active pharmaceutical ingredients, which will be used for molecule revitalization.

LGM expands its services for section 503B APIs

15-Jul-2019 By Vassia Barba

LGM expands its service offerings to further support companies that supply APIs to compounding pharmacies under the FDA’s 503B section.

Piramal expands high potency API facility in Michigan

27-Jun-2019 By Vassia Barba

Piramal’s $10m expansion at its site in Michigan supports ‘dramatic growth’ and ‘brings more to the table’.

Lonza ups HPAPI encapsulation capacity in Florida

22-Feb-2018 By Staff Reporter

Lonza has increased its encapsulation capacity and invested in highly potent active pharmaceutical ingredient (HPAPI) services at a facility in Tampa, Florida.

Pfizer pulls batches of antibiotic in Australia over anaphylaxis risk

19-Oct-2017 By Gareth Macdonald

Pfizer has recalled 10 batches of gentamicin in Australia because of problems with an API supplied by a third party.

Update

Piramal boosts HPAPI site in Michigan, US

11-Oct-2017 By Flora Southey

Piramal Pharma Solutions will expand its high potency active pharmaceutical ingredient (HPAPI) capabilities at its Riverview site in Michigan, US.

AkzoNobel ups pharma salt capacity in Denmark

10-Oct-2017 By Dan Stanton

AkzoNobel has expanded a facility in Denmark on the back of high demand for pharmaceutical grade salt.

Merck & Co API operations hit by cyberattack yet to restart production

31-Jul-2017 By Gareth Macdonald

API operations hit by the Petya cyberattack have not been restored according to Merck & Co Inc, which expects difficulties fulfilling some product orders and lower 2017 profits partly due to the hack. 

WHO prequalifies Mylan's India unit to supply TB drug API

20-Jul-2017 By Gareth Macdonald

The WHO has prequalified Indian-based Mylan Laboratories Ltd to supply the tuberculosis drug ingredient protionamide.

Tetraphase hires Patheon to make its synthetic antibiotic eravacycline

22-Jun-2017 By Gareth Macdonald

Tetraphase Pharmaceutical has hired Patheon UK Limited to make and test the synthetic antibiotic eravacycline.

US FDA rejects Sun epilepsy drug due to ongoing problems at Halol plant

24-May-2017 By Gareth Macdonald

The US FDA has refused to reapprove Sun Pharma Advanced Research LTD’s epilepsy drug Elepsia XR (levetiracetam) citing problems at its plant in Halol, India.

The hunt for work after red October: Novo cites military experience as a big plus

02-Sep-2015 By Gareth Macdonald

Novo Nordisk says nuclear submarine veterans’ “mission critical” mentality is suited to pharmaceutical manufacturing environment.

API facility issues cause FDA to reject Pozen drug candidates

29-Apr-2014 By Zachary Brennan

Deficiencies of at an unnamed API supplier caused the US FDA to reject Pozen’s aspirin-based drug candidates with a complete response letter (CRL).

Shasun Plant Gets Third Regulatory Thumbs Up in As Many Months

03-Sep-2013 By Gareth Macdonald

The UK MHRA has given Shansun Pharmaceutical’s drug formulation plant in Puducherry, India a clean bill of health after an inspection last month.

Strike Ends at Shasun API Plant but Share Price Takes Hit

02-Jul-2013

Operations have restarted at one of Shasun’s API facilities in India following a strike last month.

Genentech warns of fake Avastin

15-Feb-2012

Genentech is warning patients that counterfeiters have distributed fake Avastin, which lacks the API bevacizumab, in the US.

Appointments at Sproxil, Intercell and Evolva Holding – People on the move

10-May-2011 By Nick Taylor

in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Sproxil, Intercell and Evolva Holding.

Space, the final frontier for drug stability says NASA study

27-Apr-2011 By Gareth Macdonald

The finding that space flight is detrimental to drug stability may have implications for drug packaging, dispensing technologies and mail order delivery according to a NASA study.

Appointments at NormOxys, Caraco, Shire and ChemWorth – People on the move

12-Oct-2010 By Nick Taylor

in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at NormOxys, Caraco, Shire and ChemWorth.

Irish pharma sector must attract R&D to secure competitve edge, says PCI

18-Mar-2010 By Gareth Macdonald

Ireland must become an R&D hub as well as a drug manufacturing destination to prosper in the increasingly competitive global pharmaceutical market, says industry body PharmaChemical Ireland (PCI).

Cambrex’s revenues dip in 2009; forecast flat for 2010

11-Feb-2010 By Nick Taylor

Cambrex reported a dip in revenues in 2009, citing the timing of orders throughout the year, and warned that smaller clients’ funding difficulties and pricing pressures will continue in 2010.

SAFC showcases HPAPI handling capabilities

30-Oct-2008 By Gareth Macdonald

SAFC's Mike Harris sets out the firm's role in the expanding high-potency active pharmaceutical ingredient (HPAPI) industry.

Hovione makes latest investment in China

10-Mar-2008 By Kirsty Barnes

Portugal's Hovione has become the latest in a spate of pharma
industry players to invest further in China.

People on the move

14-Oct-2004

In-Pharmatechnologist's periodic round up of personnel moves in the
pharmaceutical sector includes a crop of new chief executives and
senior managers across the pharmachem, drug delivery and
biomanufacturing sectors.

Indena process opens up taxane chemistry

24-Aug-2004

The taxane class of cancer drugs has established itself as a
mainstay in the treatment of a range of solid tumours, but to date
there are still only two of these compounds on the market.

New helmsman at Cambrex

20-Nov-2003

Cambrex has appointed a new CEO to oversee the combination of its
small-molecule and biological active pharmaceutical ingredient
(API) activities into a single business unit.